Core Viewpoint - The recent drastic price drop of Labubu blind boxes in the secondary market highlights the cyclical nature of capital speculation, transitioning from hype to collapse [1] Group 1: Product Overview - Labubu is a plastic doll from Pop Mart, marketed as a blind box collectible [3] - The product was previously sold at inflated prices, with individual dolls fetching up to ten times their original price due to perceived scarcity [3] Group 2: Market Dynamics - The price collapse was triggered by a sudden large-scale restock during the 618 shopping festival, which shattered the illusion of scarcity [3][4] - The brand employed a strategy of "hunger marketing" combined with periodic restocking to create initial scarcity and drive up market interest [4] Group 3: Speculation and Consumer Behavior - Speculators and middlemen exploited information asymmetry and technology to hoard products, misleading consumers about their investment value [4] - The true production cost of the dolls is relatively low, indicating that the perceived value is artificially constructed [5] Group 4: Investment Insights - The article warns against investing in products driven by speculative hype rather than intrinsic value, emphasizing the importance of companies with genuine innovation and brand strength [5] - The collapse of Labubu's prices serves as a reminder that speculative bubbles inevitably burst, reinforcing the principle that detached speculation from actual value leads to failure [5]

Core Viewpoint - The ongoing debate between hyaluronic acid and recombinant collagen in the capital market highlights the challenges faced by companies like Huaxi Biological, which is experiencing a decline in revenue and net profit after reaching a peak in 2022 [2][6]. Group 1: Company Response and Market Dynamics - Huaxi Biological criticized the recent reports from several securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports misrepresent the safety and efficacy of hyaluronic acid [3][4]. - The company emphasized the importance of a healthy industry ecosystem, stating that without it, no company can achieve long-term success or maintain competitive advantages [5][6]. - Huaxi Biological is undergoing a comprehensive management transformation in 2024, including business process restructuring and digitalization, to address the challenges in the current operating environment [2][6]. Group 2: Financial Performance - In 2024, Huaxi Biological reported a revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [6]. - The skin science innovation business, which accounts for nearly half of the company's revenue, saw a significant decline of 31.62% in revenue, totaling 2.569 billion yuan [6]. - In contrast, the medical terminal business achieved a revenue of 1.44 billion yuan in 2024, marking a growth of 32.03% [7]. Group 3: Industry Trends and Competition - The medical aesthetics industry is witnessing a shift from hyaluronic acid to recombinant collagen and other regenerative products, driven by evolving consumer preferences and technological advancements [5][9]. - The market for recombinant collagen is growing rapidly, with companies like Jinbo Biological and Giant Bio achieving substantial revenue increases in 2024, indicating a competitive landscape with low market concentration [8][9]. - Huaxi Biological is also investing in recombinant collagen research and development, aiming to leverage synthetic biology for technological upgrades and high-quality applications [7][8].